Novartis AG submitted its Q3 2024 Financial Report to the U.S. Securities and Exchange Commission (SEC) on October 29, 2024. The company filed Form 6-K, which is used by foreign private issuers to furnish information to the SEC.The filing includes two key exhibits: the Financial Report for Q3 2024 and the Interim Financial Report. These documents likely contain detailed information about Novartis's financial performance and position for the quarter ended September 30, 2024.Paul Penepent, Head of Financial Reporting and Accounting at Novartis, signed the report on behalf of the company. This routine filing complies with SEC regulations for foreign companies listed on U.S. exchanges, ensuring transparency for investors and regulators.

Novartis AG submitted its Q3 2024 Financial Report to the U.S. Securities and Exchange Commission (SEC) on October 29, 2024. The company filed Form 6-K, which is used by foreign private issuers to furnish information to the SEC.The filing includes two key exhibits: the Financial Report for Q3 2024 and the Interim Financial Report. These documents likely contain detailed information about Novartis's financial performance and position for the quarter ended September 30, 2024.Paul Penepent, Head of Financial Reporting and Accounting at Novartis, signed the report on behalf of the company. This routine filing complies with SEC regulations for foreign companies listed on U.S. exchanges, ensuring transparency for investors and regulators.